Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Positive Osteoarthritis Efficacy Results For Ketoprofen Buoy Endo

This article was originally published in The Pink Sheet Daily

Executive Summary

Endo also reports strong third quarter sales driven by Lidoderm pain patch.

You may also be interested in...



Orexo Files NDA For Dissolving Zolpidem

Payers likely to favor generic Ambien for short-term insomnia, analyst tells “The Pink Sheet” DAILY.

Orexo Files NDA For Dissolving Zolpidem

Payers likely to favor generic Ambien for short-term insomnia, analyst tells “The Pink Sheet” DAILY.

Endo Financials Strong, But Shareholder Calls For Sale Of Company

CEO stepping down and no R&D leader on board, as officials evaluate pipeline.

Topics

UsernamePublicRestriction

Register

ID1131849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel